Abstract: The present invention relates to a disintegrant free pharmaceutical composition comprising apremilast or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients. Particularly the present invention relates to disintegrant free immediate release dosage form comprising apremilast or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients. It further relates to process of preparing such composition and its use in psoriatic arthritis and psoriasis.

Abstract: A pharmaceutical composition containing cinacalcet or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients. A pharmaceutical composition containing cinacalcet or pharmaceutically acceptable salts thereof having a particle size distribution D90 equal to or less than 20 ?m, D50 equal to or less than 10 ?m, and D10 equal to or less than 5 ?m and one or more and binders in an amount of 0.9% w/w or less, relative to the total weight of composition, where the composition is not free of binder and that the total amount of binder does not exceed 0.9% w/w relative to the total weight of the composition.

Abstract: The invention relates to vortioxetine hydrobromide having particle size distribution of D98 100-200?, D50 35-90? and D5 7-30? as well as to a stable, reproducible and bioequivalent pharmaceutical composition comprising vortioxetine hydrobromide having particle size distribution of D98 100-200?, D50 35-90? and D5 7-30? and one or more pharmaceutically acceptable excipient. It is produced by wet granulation techniques.

Abstract: The present disclosure relates to a stable, reproducible and bioequivalent apixaban compositions, wherein the composition comprising apixaban having a D90 particle size of more than 100 microns, preferably between 300 and 1000 microns, and more preferably between 350 and 800 microns, and further comprising one or more pharmaceutically acceptable excipients. The present disclosure further provides a process for preparation of a pharmaceutical composition comprising apixaban by wet granulation.

Abstract: A system and method to auto-determine and install missing components to a to a to-be-managed device by a single execution of unique device setup command has been described. Initially based on a received request, a unique device setup command is generated to on board a device on cloud device management system. Next the unique device setup command is executed that executes several operations including: auto-determining whether the device has required Operating System (OS), system architecture, and one or more software components including a control panel slave to allow retrieval of device monitoring data from the device. The execution of unique device address also execute the operation of installing a control plane slave on the device in communication with a control plane master at the cloud device management system to manage the plurality of devices, when the device has the required OS, architecture, and the one or more software components.

Abstract: A system and method to generate and deploy a customized cloud device application has been described. A platform broker analyzes a deployment information of a software service included in the customized cloud device application. Based on the analysis, the platform broker determines whether the software service is to be deployed at a cloud resource or devices. Based on the determination and a composition pattern, the platform broker sends a software service deployment request to a cloud broker and a device broker. Based on the software service deployment request, an instance of the software service generates and deploys the generated instance of the software service to one of the cloud resource and the one or more devices. Finally, the generated instance of the customized cloud device application bound to the deployed instance of the software service is deployed to one of the one or more cloud resources and the device.

Abstract: A system and method to build and deploy a cloud device application a cloud and a plurality of devices has been described. Initially a selection of software executable code and runtime architecture of one of the cloud and the plurality of devices is received for deploying the cloud device application including the software executable code. Next a builder image is selected for generating a software executable image corresponding to the software executable code. Next a build process is executed to generate the software executable image corresponding to the software executable code based on the selected builder process. Finally the generated software executable image on one of the cloud and one of the plurality of devices is deployed based on the runtime architecture.

Abstract: A system and method to manage a plurality of devices has been described. Initially a device manager server in a cloud device management system, sends a selection of one or more device monitoring parameters to retrieve device monitoring data from a device from the plurality of devices. Next a device monitoring data is received corresponding to the selected one or more device monitoring parameters retrieved from the device and stored in one of a log database and a metric database at the cloud device management system. Next one or more device monitoring data are executed at the cloud device management system based on the device monitoring data stored at the log database and the metric database. Finally the result of execution is displayed at a console of the cloud device management system.

Abstract: A system and method to generate and deploy a cloud device application has been described. Initially a software service is selected from a software service store to generate the cloud device application. A selection of composition pattern is then received for generating a cloud device application including the software service. Based on the composition pattern an instance of the software service is generated and deployed at cloud and one or more devices. Next an instance of the application is generated and bound to the deployed instance of the software service. Finally the instance of the application bound to the deployed instance of the software service is deployed to the cloud and the one or more devices.

Abstract: A system and method to manage communication between a plurality of heterogeneous devices and a cloud has been described. A speaker communication property of a speaker node executing at one of the plurality of heterogeneous devices and the cloud in a first network is compared with a listener communication property of a listener node executing at another of the plurality of devices in a second network. A message-type agnostic speaker proxy included in the first network is then generated based on the comparison. Next a message-type agnostic buffer including serialized message corresponding to a message send by the speaker node is received at the first communication bridge in the first network. Finally, the message-type agnostic speaker proxy forwards the serialized message included in the message-type agnostic buffer to the listener node in the first network.

Abstract: The present invention discloses simple process for preparation of salt of polyallylamine polymer.

Abstract: The present invention discloses a novel process for preparation of carvedilol by using eco friendly solvents to obtain the said carvedilol in high purity. The said process comprises, reacting 4-hydroxy carbazole of formula (IV) with epichlorhydrin in presence of an organic solvent and a base at temperatures between 10° C.-30° C.; further reacting the resultant 4-(2,3-epoxypropoxy)- carbazole of formula (II) with a salt of 2-(2-methoxyphenoxy)ethylamine of formula (III), preferably hydrochloride salt in presence of a base and a hydroxylic solvent at temperatures between 30° C.-90° C.

Abstract: The present invention discloses a novel, stable polymorph of 1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride commonly known as Donepezil hydrochloride. Further the present invention discloses a process for producing Donepezil HCl amorphous and its polymorph Form (VI).

Abstract: The present invention relates to an improved process for the preparation of 5,6-dihydro-4-(S)-(ethylamino)-6-(S)methyl-4H-thieno[2,3b]thiopyran-2-sulphonamide-7,7-dioxide hydrochloride of formula (I) commonly known as Dorzolamide Hydrochloride useful as an agent to reduce intraoccular pressure by inhibiting carbonic anhydrase enzyme

Abstract: A process for making Clopidogrel Bisulfate Form I which comprises dissolving Clopidogrel Bisulfate Form II in a solublizing solvent at room temperature to form a solution; adding an anti-solvent to the said solution till turbid; stirring the said turbid solution; collecting the precipitated solid and drying the final solid product, form I.

Abstract: The present invention discloses a novel, stable polymorph of 1-benzyl-4[(5,6-dimethoxy-1-indanone)-2-yl]methyl piperidine hydrochloride commonly known as Donepezil hydrochloride. Further the present invention discloses a process for producing Donepezil HCl amorphous and its polymorph Form (VI).

Abstract: The present invention discloses a novel process and novel intermediates for the Preparation of 4-[2-(di-n-propyl amino) ethyl]-1,3-dihydro-2H-indol-2-one, commonly known as Ropinirole (I) and pharmaceutical composition comprising the same. Further the present invention also discloses a method of treatment for cardiovascular disorders and Parkinson's disease.

Abstract: The present invention relates to the oxalate salt of 1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl]methyl piperidine, commonly known as Donepezil, and its method of preparation.